Cargando…
Stakeholder Perspectives of Australia’s National HPV Vaccination Program
Australia has been a world leader in human papillomavirus (HPV) vaccination and was the first country to implement a fully funded national HPV vaccination program, from 2007 for girls and 2013 for boys. In 2018 the program changed from a 4-valent to 9-valent HPV vaccine and a 3-dose to 2-dose standa...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692920/ https://www.ncbi.nlm.nih.gov/pubmed/36423072 http://dx.doi.org/10.3390/vaccines10111976 |
_version_ | 1784837396877017088 |
---|---|
author | Swift, Caitlin Dey, Aditi Rashid, Harunor Clark, Katrina Manocha, Ramesh Brotherton, Julia Beard, Frank |
author_facet | Swift, Caitlin Dey, Aditi Rashid, Harunor Clark, Katrina Manocha, Ramesh Brotherton, Julia Beard, Frank |
author_sort | Swift, Caitlin |
collection | PubMed |
description | Australia has been a world leader in human papillomavirus (HPV) vaccination and was the first country to implement a fully funded national HPV vaccination program, from 2007 for girls and 2013 for boys. In 2018 the program changed from a 4-valent to 9-valent HPV vaccine and a 3-dose to 2-dose standard schedule. We assessed stakeholder perspectives on factors influencing program outcomes and impact as part of a comprehensive program evaluation. In late 2019 and early 2020, we conducted 26 interviews with 42 key stakeholder participants and received 1513 survey responses from stakeholders including general practice staff and school-based nurse immunisers. Findings included that the 2-dose schedule is better accepted by schools and students and has reduced program cost and resource requirements. However, course completion rates have not increased as much as anticipated due to the 6–12 month dosing interval and reduced opportunities for school-based catch-up vaccination. Major reported barriers to increased vaccine coverage were absenteeism and consent form return. Vaccine hesitancy is not currently a major issue but remains a potential threat to the program. While Australia’s HPV vaccination program is perceived as highly successful, measures to further enhance the program’s impact and mitigate potential threats are important. |
format | Online Article Text |
id | pubmed-9692920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96929202022-11-26 Stakeholder Perspectives of Australia’s National HPV Vaccination Program Swift, Caitlin Dey, Aditi Rashid, Harunor Clark, Katrina Manocha, Ramesh Brotherton, Julia Beard, Frank Vaccines (Basel) Article Australia has been a world leader in human papillomavirus (HPV) vaccination and was the first country to implement a fully funded national HPV vaccination program, from 2007 for girls and 2013 for boys. In 2018 the program changed from a 4-valent to 9-valent HPV vaccine and a 3-dose to 2-dose standard schedule. We assessed stakeholder perspectives on factors influencing program outcomes and impact as part of a comprehensive program evaluation. In late 2019 and early 2020, we conducted 26 interviews with 42 key stakeholder participants and received 1513 survey responses from stakeholders including general practice staff and school-based nurse immunisers. Findings included that the 2-dose schedule is better accepted by schools and students and has reduced program cost and resource requirements. However, course completion rates have not increased as much as anticipated due to the 6–12 month dosing interval and reduced opportunities for school-based catch-up vaccination. Major reported barriers to increased vaccine coverage were absenteeism and consent form return. Vaccine hesitancy is not currently a major issue but remains a potential threat to the program. While Australia’s HPV vaccination program is perceived as highly successful, measures to further enhance the program’s impact and mitigate potential threats are important. MDPI 2022-11-21 /pmc/articles/PMC9692920/ /pubmed/36423072 http://dx.doi.org/10.3390/vaccines10111976 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Swift, Caitlin Dey, Aditi Rashid, Harunor Clark, Katrina Manocha, Ramesh Brotherton, Julia Beard, Frank Stakeholder Perspectives of Australia’s National HPV Vaccination Program |
title | Stakeholder Perspectives of Australia’s National HPV Vaccination Program |
title_full | Stakeholder Perspectives of Australia’s National HPV Vaccination Program |
title_fullStr | Stakeholder Perspectives of Australia’s National HPV Vaccination Program |
title_full_unstemmed | Stakeholder Perspectives of Australia’s National HPV Vaccination Program |
title_short | Stakeholder Perspectives of Australia’s National HPV Vaccination Program |
title_sort | stakeholder perspectives of australia’s national hpv vaccination program |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692920/ https://www.ncbi.nlm.nih.gov/pubmed/36423072 http://dx.doi.org/10.3390/vaccines10111976 |
work_keys_str_mv | AT swiftcaitlin stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram AT deyaditi stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram AT rashidharunor stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram AT clarkkatrina stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram AT manocharamesh stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram AT brothertonjulia stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram AT beardfrank stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram |